{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:43Z","timestamp":1792123663385,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116594","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:07:48Z","timestamp":1771358868000},"page":"116594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-4607","authenticated-orcid":false,"given":"Stefania","family":"Cuzzubbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-7061","authenticated-orcid":false,"given":"Alberto","family":"Vogrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelaine","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Philippakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-8937","authenticated-orcid":false,"given":"Renata","family":"Ursu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilien","family":"Ezine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine F.","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejca.2026.116594_bib1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116594_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.ejca.2026.116594_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116594_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001034","article-title":"Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients","volume":"8","author":"Cuzzubbo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116594_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102376","article-title":"Emergence of ocular toxicities associated with novel anticancer therapeutics: what the oncologist needs to know","volume":"105","author":"Ali","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2026.116594_bib6","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: current status and future directions","volume":"2","author":"Winges","year":"2022","journal-title":"Front Ophthalmol (Lausanne)"},{"issue":"6","key":"10.1016\/j.ejca.2026.116594_bib7","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ejca.2026.116594_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116594_bib9","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00415-021-10870-6","article-title":"How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update","volume":"269","author":"Vogrig","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116594_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp-2021-326369","article-title":"Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours","volume":"93","author":"Chompoopong","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ejca.2026.116594_bib11","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1097\/WNO.0000000000001427","article-title":"A case of pembrolizumab-induced papillitis with transverse myelitis","volume":"43","author":"Lambert-Cheatham","year":"2023","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116594_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12883-022-02987-6","article-title":"A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study","volume":"22","author":"Hirano","year":"2022","journal-title":"BMC Neurol"},{"key":"10.1016\/j.ejca.2026.116594_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.806501","article-title":"Case report: neuromyelitis optica after treatment of uveal melanoma with nivolumab and ipilimumab","volume":"12","author":"Khimani","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116594_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102451","article-title":"Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? insights from checkpoint inhibitor immune-related adverse events","volume":"46","author":"Nasralla","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ejca.2026.116594_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular adverse events associated with immune checkpoint inhibitors, a scoping review","volume":"13","author":"Martens","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.ejca.2026.116594_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13023-016-0412-4","article-title":"Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes","volume":"11","author":"Lavezzo","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.ejca.2026.116594_bib17","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00417-003-0787-5","article-title":"Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up","volume":"241","author":"Aisenbrey","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ejca.2026.116594_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103227","article-title":"Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: a systematic review","volume":"56","author":"Shahmohammadi","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.ejca.2026.116594_bib19","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s10072-023-07252-3","article-title":"Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma","volume":"45","author":"Pedrero Prieto","year":"2024","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.ejca.2026.116594_bib20","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200249","article-title":"MOG antibody-associated disease in the setting of metastatic melanoma complicated by immune checkpoint inhibitor use","volume":"11","author":"Syc-Mazurek","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.ejca.2026.116594_bib21","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/WCO.0000000000001113","article-title":"Neurological adverse events of immune checkpoint blockade: from pathophysiology to treatment","volume":"35","author":"Cuzzubbo","year":"2022","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116594_bib22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2019-321988","article-title":"Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS","volume":"91","author":"Liu","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:27:09Z","timestamp":1773235629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926003746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"alternative-id":["S0959804926003746"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116594","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116594","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116594"}}